The United Kingdom is poised to provide NHS patients with access to new medicines previously deemed unaffordable under a sweeping agreement with the United States. Under the deal, NHS expenditure
The United Kingdom is poised to provide NHS patients with access to new medicines previously deemed unaffordable under a sweeping agreement with the United States. Under the deal, NHS expenditure
In a significant shift for the UK’s life sciences sector, Syncona, the Wellcome Trust-backed FTSE 250 investment company, has revealed plans to implement an orderly wind-down of its portfolio assets.
The NHS is seeking private sector funding to address its deteriorating infrastructure and record-breaking emergency department waiting times. Amanda Pritchard, the organisation’s chief executive, has urged ministers to adopt a
Danish pharmaceutical giant Novo Nordisk, Europe’s most valuable listed company, has received a stern reprimand from the Prescription Medicines Code of Practice Authority (PMCPA) for systematically failing to disclose healthcare
A significant move in the pharmaceutical investment landscape has emerged as Carlyle-backed Abingworth seeks to raise up to £1.5 billion for clinical trials funding, marking a strategic shift towards royalty-based






